» Articles » PMID: 20840345

Comparative Trial of Moisturizer Containing Licochalcone A Vs. Hydrocortisone Lotion in the Treatment of Childhood Atopic Dermatitis: a Pilot Study

Overview
Date 2010 Sep 16
PMID 20840345
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although moisturizer usage has been considered a mainstay of treatment for atopic dermatitis (AD) patients, few clinical studies have been investigated. Recently, moisturizers containing non-steroidal anti-inflammatory agents, such as licochalcone A (LA) and vitamin B(12) are of emerging interest.

Objective: To compare the effectiveness of moisturizer containing LA with hydrocortisone (HC) lotion in treatment of childhood AD. Methods  The randomized, controlled, investigator-blinded 6-week study was conducted. Patients were administered with twice-daily application of LA lotion on one side of the body and HC lotion on the opposite side. The clinical outcome was assessed by the scoring of atopic dermatitis (SCORAD) index. The relapse rate was comparatively analysed by survival analysis.

Results: From 30 patients enrolled, 26 patients completed the protocol. The mean age of the children was 5.8 years. The average baseline SCORAD score is about 28 on both sides. The response rates of both agents were equal to 73.33%. There is no statistical significant group difference in reduction of SCORAD score. Although we observed more rapid resolution of oedema and erythema in areas treated with HC lotion, both agents exhibited no significant difference. The relapse rate of HC group was higher than in LA group; however, there was no significant difference. No side-effect was observed from both agents.

Conclusion: The effectiveness of LA lotion is equal to that of HC lotion. It was suggested that moisturizer containing LA could be used both for treatment of acute and maintenance phase in mild-to-moderate childhood AD.

Citing Articles

Topical anti-inflammatory treatments for eczema: network meta-analysis.

Lax S, Van Vogt E, Candy B, Steele L, Reynolds C, Stuart B Cochrane Database Syst Rev. 2024; 8():CD015064.

PMID: 39105474 PMC: 11301992. DOI: 10.1002/14651858.CD015064.pub2.


Recent Advances in Phytochemical-Based Topical Applications for the Management of Eczema: A Review.

Radhakrishnan J, Kennedy B, Noftall E, Giacomantonio C, Rupasinghe H Int J Mol Sci. 2024; 25(10).

PMID: 38791412 PMC: 11120771. DOI: 10.3390/ijms25105375.


Topical steroids or emollients: does order matter?.

Ahuja K, A Lio P Arch Dermatol Res. 2024; 316(4):104.

PMID: 38488957 DOI: 10.1007/s00403-024-02837-0.


How and what adverse events are reported and captured in randomized control trials of emollients in the treatment of eczema?.

Emmett E, Allen M, Crownshaw S, Ridd M Clin Exp Dermatol. 2023; 48(8):889-894.

PMID: 37075240 PMC: 10359396. DOI: 10.1093/ced/llad137.


Pharmacological Properties of Chalcones: A Review of Preclinical Including Molecular Mechanisms and Clinical Evidence.

Salehi B, Quispe C, Chamkhi I, El Omari N, Balahbib A, Sharifi-Rad J Front Pharmacol. 2021; 11:592654.

PMID: 33536909 PMC: 7849684. DOI: 10.3389/fphar.2020.592654.